BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 24, 2005
View Archived Issues
Amylin Publicly Raises $176M To Fund Symlin, Exenatide Plans
Read More
Mutations In Mitochondrion Affect Prostate Cancer Risk
Read More
Schering-Plough Plans Buyout Of Platform Firm NeoGenesis
Read More
Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger
Read More
ViaCell Prices At Low End, But Gets $52.5M In 2005's First IPO
Read More
Other News To Note
Read More
Ambit Hits A Triple, Signs BMS, GSK, Pfizer To Deals
Ambit Biosciences Inc.'s super-multi-tasking approach to kinase screening bagged the company deals with three of pharma's top players - Bristol-Myers Squibb Co., GlaxoSmithKline plc and Pfizer Inc. (BioWorld Today)
Read More
